Zobrazeno 1 - 10
of 308
pro vyhledávání: '"Sheng‐Long Ye"'
Autor:
Masatoshi Kudo, Kwang-Hyub Han, Sheng-Long Ye, Jian Zhou, Yi-Hsiang Huang, Shi-Ming Lin, Chung-Kwe Wang, Masafumi Ikeda, Stephen Lam Chan, Su Pin Choo, Shiro Miyayama, Ann Lii Cheng
Publikováno v:
Liver Cancer, Vol 9, Iss 3, Pp 245-260 (2020)
The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APP
Externí odkaz:
https://doaj.org/article/10dc796a200244dc9411f022c236f9fa
Autor:
Gang Dong, Qiong‐Dan Zheng, Min Ma, Si‐Fan Wu, Rui Zhang, Rong‐Rong Yao, Yin‐Ying Dong, Hui Ma, Dong‐Mei Gao, Sheng‐Long Ye, Jie‐Feng Cui, Zheng‐Gang Ren, Rong‐Xin Chen
Publikováno v:
Cancer Medicine, Vol 7, Iss 3, Pp 820-830 (2018)
Abstract Transarterial chemoembolization (TACE) is the standard treatment for unresectable hepatocellular carcinoma (HCC). Hypoxia‐induced angiogenesis by TACE is linked to treatment failure; however, whether the chemotherapeutic damage of TACE to
Externí odkaz:
https://doaj.org/article/9308aecb0206439e869da4d4aa51e51a
Autor:
Sheng-Long Ye, Jiamei Yang, Ping Bie, Shuijun Zhang, Xiaoping Chen, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Zhengguang Lv
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients. Methods A subgroup of 345 Chinese patients from the international database of the Global Inves
Externí odkaz:
https://doaj.org/article/de713bec64504cb39c204547b7a1a1f2
Autor:
Xing-Hao, Zhou, Jing-Ru, Li, Tang-Hui, Zheng, Hong, Chen, Chen, Cai, Sheng-Long, Ye, Bo, Gao, Tong-Chun, Xue
Publikováno v:
Clinical & Experimental Metastasis. 40:5-32
Portal vein tumor thrombosis (PVTT), a common complication of advanced hepatocellular carcinoma (HCC), remains the bottleneck of the treatments. Liver cancer cells potentially experienced multi-steps during PVTT process, including cancer cells leave
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182d6bace0fb9b63e5be12fa92d19765
https://doi.org/10.1007/s10585-022-10188-1
https://doi.org/10.1007/s10585-022-10188-1
Publikováno v:
Chinese Medical Journal, Vol 130, Iss 12, Pp 1395-1399 (2017)
Background: Antiphospholipid syndrome (APS)-related immune factors are considered as an important cause of recurrent spontaneous abortion (RSA). Anticoagulant and anti-inflammatory treatments are believed to effectively improve adverse pregnancy outc
Externí odkaz:
https://doaj.org/article/d9704a8f5031457990c7ed386900a315
Autor:
Hong Zhang, James G. Karras, Youngsoo Kim, Zhao-You Tang, Yin-Kun Liu, Rui-Xia Sun, Sheng-Long Ye, Wen-Chang Li
Supplementary Figures 1-2 from Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f19c410d4d3549666e8645423e4287b
https://doi.org/10.1158/1078-0432.22441243.v1
https://doi.org/10.1158/1078-0432.22441243.v1
Autor:
Hong Zhang, James G. Karras, Youngsoo Kim, Zhao-You Tang, Yin-Kun Liu, Rui-Xia Sun, Sheng-Long Ye, Wen-Chang Li
Supplementary Materials and Figure Legends 1-2 from Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0beb4ea700f2b8b17cf77fca2f88764a
https://doi.org/10.1158/1078-0432.22441240
https://doi.org/10.1158/1078-0432.22441240
Autor:
Hong Zhang, James G. Karras, Youngsoo Kim, Zhao-You Tang, Yin-Kun Liu, Rui-Xia Sun, Sheng-Long Ye, Wen-Chang Li
Purpose: Hepatocellular carcinoma (HCC) is an aggressive malignancy and is a devastating clinical complication of chronic liver disease. Therapeutic options are limited mainly because the genetic and biochemical understanding of this disease remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c87bca438910e76219d389df5091d48
https://doi.org/10.1158/1078-0432.c.6518362
https://doi.org/10.1158/1078-0432.c.6518362
Autor:
Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Christina SM Yip, Xiaolei Yang
Publikováno v:
Tumor Biology, Vol 39 (2017)
The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma. Data of 338 Chinese patients from the Global Investigation of therapeutic DEcisions in hepatocellular carcin
Externí odkaz:
https://doaj.org/article/038d0c30c39047b19c5b450e072dae3c
Autor:
Sheng Long Ye, Jian Zhou, Shiro Miyayama, Su Pin Choo, Ann-Lii Cheng, Yi Hsiang Huang, Shi-Ming Lin, Kwang Hyub Han, Chung Kwe Wang, Stephen L. Chan, Masafumi Ikeda, Masatoshi Kudo
Publikováno v:
Liver Cancer, Vol 9, Iss 3, Pp 245-260 (2020)
Liver Cancer
Liver Cancer
The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f0af13c947d622eaa98ef0a0c4ef97e
https://doi.org/10.1159/000507370
https://doi.org/10.1159/000507370